Adverse body composition and lipid parameters in patients with prolactinoma: a case-control study View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2021-04-26

AUTHORS

Anna Sophia Posawetz, Christian Trummer, Marlene Pandis, Felix Aberer, Thomas R. Pieber, Barbara Obermayer-Pietsch, Stefan Pilz, Verena Theiler-Schwetz

ABSTRACT

BackgroundHyperprolactinaemia might cause adverse metabolic effects. The aim of our study was to compare parameters of body composition, glucose and lipid metabolism between untreated patients with prolactinoma and controls and to assess changes after initiation of cabergoline.MethodsCase-control study with a retrospectively analyzed follow-up in patients with prolactinoma after initiation of cabergoline therapy.Results21 patients with prolactinoma (9 micro- and 12 macroprolactinomas; 7 females) and 30 controls were analyzed. Patients with prolactinoma had significantly higher BMI than controls; fat mass did not differ between groups. Only men - but not women - with prolactinoma had significantly higher fat mass at all six sites measured compared to controls. Levels of LDL (130 (107–147.5) vs. 94.5 (80–127.5) mg/dl, p < 0.001) were significantly higher, levels of HDL (56 ± 16.7 vs. 69.2 ± 14.6 mg/dl, p = 0.004) significantly lower than in controls. Fasting glucose, HOMA-IR, HbA1c, adiponectin, CRP, and homocysteine did not differ between groups.After a median of 10 weeks (IQR 7–18 weeks) after initiation of cabergoline, total (from 212.5 ± 36.2 to 196.9 ± 40.6 mg/dl, p = 0.018) and LDL cholesterol (130 (107–147.5) to 106.5 (94.3–148) mg/dl, p = 0.018) had significantly decreased. Analyzing men and women separately, this change occurred in men only.ConclusionsReasons for the association between prolactin and metabolic parameters include direct effects of prolactin on adipose tissue, hyperprolactinaemia-triggered hypogonadism and dopamine-agonist therapy per se. Altered lipid metabolism in patients with prolactinoma might imply an increased cardiovascular risk, highlighting the necessity to monitor metabolic parameters in these patients. More... »

PAGES

81

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12902-021-00733-6

DOI

http://dx.doi.org/10.1186/s12902-021-00733-6

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1137484146

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/33902531


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adiposity", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Austria", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Body Composition", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Body Mass Index", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cabergoline", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Case-Control Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dyslipidemias", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hyperprolactinemia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lipid Metabolism", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Overweight", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pituitary Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prolactinoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria", 
          "id": "http://www.grid.ac/institutes/grid.11598.34", 
          "name": [
            "Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Posawetz", 
        "givenName": "Anna Sophia", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria", 
          "id": "http://www.grid.ac/institutes/grid.11598.34", 
          "name": [
            "Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Trummer", 
        "givenName": "Christian", 
        "id": "sg:person.01201252150.71", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01201252150.71"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria", 
          "id": "http://www.grid.ac/institutes/grid.11598.34", 
          "name": [
            "Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pandis", 
        "givenName": "Marlene", 
        "id": "sg:person.015231525635.58", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015231525635.58"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria", 
          "id": "http://www.grid.ac/institutes/grid.11598.34", 
          "name": [
            "Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Aberer", 
        "givenName": "Felix", 
        "id": "sg:person.01351004310.93", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01351004310.93"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria", 
          "id": "http://www.grid.ac/institutes/grid.11598.34", 
          "name": [
            "Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pieber", 
        "givenName": "Thomas R.", 
        "id": "sg:person.0757263437.98", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0757263437.98"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria", 
          "id": "http://www.grid.ac/institutes/grid.11598.34", 
          "name": [
            "Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Obermayer-Pietsch", 
        "givenName": "Barbara", 
        "id": "sg:person.01071524655.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01071524655.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria", 
          "id": "http://www.grid.ac/institutes/grid.11598.34", 
          "name": [
            "Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pilz", 
        "givenName": "Stefan", 
        "id": "sg:person.0751717266.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0751717266.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria", 
          "id": "http://www.grid.ac/institutes/grid.11598.34", 
          "name": [
            "Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Theiler-Schwetz", 
        "givenName": "Verena", 
        "id": "sg:person.011457756430.96", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011457756430.96"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s12020-012-9857-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032398967", 
          "https://doi.org/10.1007/s12020-012-9857-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf03345636", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028831522", 
          "https://doi.org/10.1007/bf03345636"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11011-016-9882-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034492836", 
          "https://doi.org/10.1007/s11011-016-9882-2"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2021-04-26", 
    "datePublishedReg": "2021-04-26", 
    "description": "BackgroundHyperprolactinaemia might cause adverse metabolic effects. The aim of our study was to compare parameters of body composition, glucose and lipid metabolism between untreated patients with prolactinoma and controls and to assess changes after initiation of cabergoline.MethodsCase-control study with a retrospectively analyzed follow-up in patients with prolactinoma after initiation of cabergoline therapy.Results21 patients with prolactinoma (9 micro- and 12 macroprolactinomas; 7 females) and 30 controls were analyzed. Patients with prolactinoma had significantly higher BMI than controls; fat mass did not differ between groups. Only men - but not women - with prolactinoma had significantly higher fat mass at all six sites measured compared to controls. Levels of LDL (130 (107\u2013147.5) vs. 94.5 (80\u2013127.5) mg/dl, p\u2009<\u20090.001) were significantly higher, levels of HDL (56\u2009\u00b1\u200916.7 vs. 69.2\u2009\u00b1\u200914.6\u2009mg/dl, p\u2009=\u20090.004) significantly lower than in controls. Fasting glucose, HOMA-IR, HbA1c, adiponectin, CRP, and homocysteine did not differ between groups.After a median of 10\u2009weeks (IQR 7\u201318\u2009weeks) after initiation of cabergoline, total (from 212.5\u2009\u00b1\u200936.2 to 196.9\u2009\u00b1\u200940.6\u2009mg/dl, p\u2009=\u20090.018) and LDL cholesterol (130 (107\u2013147.5) to 106.5 (94.3\u2013148) mg/dl, p\u2009=\u00a00.018) had significantly decreased. Analyzing men and women separately, this change occurred in men only.ConclusionsReasons for the association between prolactin and metabolic parameters include direct effects of prolactin on adipose tissue, hyperprolactinaemia-triggered hypogonadism and dopamine-agonist therapy per se. Altered lipid metabolism in patients with prolactinoma might imply an increased cardiovascular risk, highlighting the necessity to monitor metabolic parameters in these patients.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s12902-021-00733-6", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1028426", 
        "issn": [
          "1472-6823"
        ], 
        "name": "BMC Endocrine Disorders", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "21"
      }
    ], 
    "keywords": [
      "initiation of cabergoline", 
      "fat mass", 
      "metabolic parameters", 
      "body composition", 
      "lipid metabolism", 
      "MethodsCase-control study", 
      "dopamine agonist therapy", 
      "adverse body composition", 
      "increased cardiovascular risk", 
      "adverse metabolic effects", 
      "levels of HDL", 
      "higher fat mass", 
      "levels of LDL", 
      "case-control study", 
      "Altered lipid metabolism", 
      "cabergoline therapy", 
      "untreated patients", 
      "HOMA-IR", 
      "cardiovascular risk", 
      "LDL cholesterol", 
      "lipid parameters", 
      "higher BMI", 
      "metabolic effects", 
      "prolactinomas", 
      "patients", 
      "adipose tissue", 
      "cabergoline", 
      "therapy", 
      "men", 
      "prolactin", 
      "only men", 
      "women", 
      "direct effect", 
      "metabolism", 
      "glucose", 
      "initiation", 
      "HbA1c", 
      "adiponectin", 
      "BMI", 
      "hypogonadism", 
      "group", 
      "LDL", 
      "control", 
      "CRP", 
      "HDL", 
      "cholesterol", 
      "homocysteine", 
      "weeks", 
      "ConclusionsReasons", 
      "study", 
      "median", 
      "levels", 
      "total", 
      "risk", 
      "tissue", 
      "association", 
      "effect", 
      "aim", 
      "changes", 
      "mass", 
      "sites", 
      "parameters", 
      "necessity", 
      "composition"
    ], 
    "name": "Adverse body composition and lipid parameters in patients with prolactinoma: a case-control study", 
    "pagination": "81", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1137484146"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12902-021-00733-6"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "33902531"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12902-021-00733-6", 
      "https://app.dimensions.ai/details/publication/pub.1137484146"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:49", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_904.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s12902-021-00733-6"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12902-021-00733-6'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12902-021-00733-6'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12902-021-00733-6'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12902-021-00733-6'


 

This table displays all metadata directly associated to this object as RDF triples.

264 TRIPLES      21 PREDICATES      112 URIs      101 LITERALS      27 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12902-021-00733-6 schema:about N07a493e6e60d4f6b8d743953c447a2bc
2 N085d4106c1994de49f31830b1f85f8a2
3 N0c4142e2f96b4a9db976e335cb0137d8
4 N17fe42171949458599fc040af0713813
5 N45ae3c4135aa4ab48e85884cf665d188
6 N4d0cdcaddd0f4e9ebd722bc371650af9
7 N5b572f5821bf4af78461ccb3b491ca0d
8 N5e868931896542f2b5329a5a25e9eae8
9 N7686d27e7c1a4cfba2fc1b7ffc49990c
10 N779b7c7f5088463abb612a90c7593f1b
11 N7ac13299800a4ba2a568b3fae599705f
12 N7b97f25c25584e38837ba6ad0943866c
13 N80e22f95b21d4b3ca7c2937c82e7a7a4
14 N8fb55d9b26e44541afefaf237e0f187d
15 Nbef3386f114e40b8a8fc7fa5a962b8da
16 Nc481c19721174401812856ffca695b7d
17 Nce6bd85ce846484696ebaf003ae74f22
18 Ncf70c322d48b410bae3d4b63bdf0aa3c
19 Nd5846dd7211d4fb383d8c079a53f3a6f
20 Nec57d0e2b10e48638493d8124ea9cbe9
21 anzsrc-for:11
22 anzsrc-for:1103
23 schema:author Nb41ccba8d81848d6949716d1028b18aa
24 schema:citation sg:pub.10.1007/bf03345636
25 sg:pub.10.1007/s11011-016-9882-2
26 sg:pub.10.1007/s12020-012-9857-y
27 schema:datePublished 2021-04-26
28 schema:datePublishedReg 2021-04-26
29 schema:description BackgroundHyperprolactinaemia might cause adverse metabolic effects. The aim of our study was to compare parameters of body composition, glucose and lipid metabolism between untreated patients with prolactinoma and controls and to assess changes after initiation of cabergoline.MethodsCase-control study with a retrospectively analyzed follow-up in patients with prolactinoma after initiation of cabergoline therapy.Results21 patients with prolactinoma (9 micro- and 12 macroprolactinomas; 7 females) and 30 controls were analyzed. Patients with prolactinoma had significantly higher BMI than controls; fat mass did not differ between groups. Only men - but not women - with prolactinoma had significantly higher fat mass at all six sites measured compared to controls. Levels of LDL (130 (107–147.5) vs. 94.5 (80–127.5) mg/dl, p < 0.001) were significantly higher, levels of HDL (56 ± 16.7 vs. 69.2 ± 14.6 mg/dl, p = 0.004) significantly lower than in controls. Fasting glucose, HOMA-IR, HbA1c, adiponectin, CRP, and homocysteine did not differ between groups.After a median of 10 weeks (IQR 7–18 weeks) after initiation of cabergoline, total (from 212.5 ± 36.2 to 196.9 ± 40.6 mg/dl, p = 0.018) and LDL cholesterol (130 (107–147.5) to 106.5 (94.3–148) mg/dl, p = 0.018) had significantly decreased. Analyzing men and women separately, this change occurred in men only.ConclusionsReasons for the association between prolactin and metabolic parameters include direct effects of prolactin on adipose tissue, hyperprolactinaemia-triggered hypogonadism and dopamine-agonist therapy per se. Altered lipid metabolism in patients with prolactinoma might imply an increased cardiovascular risk, highlighting the necessity to monitor metabolic parameters in these patients.
30 schema:genre article
31 schema:isAccessibleForFree true
32 schema:isPartOf N2dd116e204d643f0accd08346fa71ca2
33 N8edab4d54ec74a2b90ad40f1652ec64e
34 sg:journal.1028426
35 schema:keywords Altered lipid metabolism
36 BMI
37 CRP
38 ConclusionsReasons
39 HDL
40 HOMA-IR
41 HbA1c
42 LDL
43 LDL cholesterol
44 MethodsCase-control study
45 adiponectin
46 adipose tissue
47 adverse body composition
48 adverse metabolic effects
49 aim
50 association
51 body composition
52 cabergoline
53 cabergoline therapy
54 cardiovascular risk
55 case-control study
56 changes
57 cholesterol
58 composition
59 control
60 direct effect
61 dopamine agonist therapy
62 effect
63 fat mass
64 glucose
65 group
66 higher BMI
67 higher fat mass
68 homocysteine
69 hypogonadism
70 increased cardiovascular risk
71 initiation
72 initiation of cabergoline
73 levels
74 levels of HDL
75 levels of LDL
76 lipid metabolism
77 lipid parameters
78 mass
79 median
80 men
81 metabolic effects
82 metabolic parameters
83 metabolism
84 necessity
85 only men
86 parameters
87 patients
88 prolactin
89 prolactinomas
90 risk
91 sites
92 study
93 therapy
94 tissue
95 total
96 untreated patients
97 weeks
98 women
99 schema:name Adverse body composition and lipid parameters in patients with prolactinoma: a case-control study
100 schema:pagination 81
101 schema:productId N50a6d55f2742422d903894af30f24bd9
102 N682e3498c35a4409ac9b7cf7b836251b
103 N94ed771202904745bdc3de2fb6daba2f
104 schema:sameAs https://app.dimensions.ai/details/publication/pub.1137484146
105 https://doi.org/10.1186/s12902-021-00733-6
106 schema:sdDatePublished 2022-10-01T06:49
107 schema:sdLicense https://scigraph.springernature.com/explorer/license/
108 schema:sdPublisher N863cc56ffdd54c40a08585c3acf983c7
109 schema:url https://doi.org/10.1186/s12902-021-00733-6
110 sgo:license sg:explorer/license/
111 sgo:sdDataset articles
112 rdf:type schema:ScholarlyArticle
113 N05bb7b0865ee4bec8d9a9854a1b7d8f4 rdf:first sg:person.0751717266.10
114 rdf:rest Nafdb561d8a02461b95ef154fe989d49a
115 N07a493e6e60d4f6b8d743953c447a2bc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Body Composition
117 rdf:type schema:DefinedTerm
118 N085d4106c1994de49f31830b1f85f8a2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Follow-Up Studies
120 rdf:type schema:DefinedTerm
121 N0c4142e2f96b4a9db976e335cb0137d8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Lipid Metabolism
123 rdf:type schema:DefinedTerm
124 N0f58029d5368401cadaf071969c32e2f rdf:first sg:person.01351004310.93
125 rdf:rest Nb77f05813f9943b58d38ffb5dc7b5763
126 N17fe42171949458599fc040af0713813 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Cabergoline
128 rdf:type schema:DefinedTerm
129 N2dd116e204d643f0accd08346fa71ca2 schema:issueNumber 1
130 rdf:type schema:PublicationIssue
131 N34bfcc3e3f7d4fbcbccbc176727d8fe2 rdf:first sg:person.015231525635.58
132 rdf:rest N0f58029d5368401cadaf071969c32e2f
133 N45ae3c4135aa4ab48e85884cf665d188 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Prolactinoma
135 rdf:type schema:DefinedTerm
136 N4d0cdcaddd0f4e9ebd722bc371650af9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Young Adult
138 rdf:type schema:DefinedTerm
139 N50a6d55f2742422d903894af30f24bd9 schema:name doi
140 schema:value 10.1186/s12902-021-00733-6
141 rdf:type schema:PropertyValue
142 N5b572f5821bf4af78461ccb3b491ca0d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Adult
144 rdf:type schema:DefinedTerm
145 N5e868931896542f2b5329a5a25e9eae8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Middle Aged
147 rdf:type schema:DefinedTerm
148 N672a52087c6b41de83fac25ad5d79ea9 schema:affiliation grid-institutes:grid.11598.34
149 schema:familyName Posawetz
150 schema:givenName Anna Sophia
151 rdf:type schema:Person
152 N682e3498c35a4409ac9b7cf7b836251b schema:name pubmed_id
153 schema:value 33902531
154 rdf:type schema:PropertyValue
155 N6f020bb623f544199c11d0d86164c11e rdf:first sg:person.01201252150.71
156 rdf:rest N34bfcc3e3f7d4fbcbccbc176727d8fe2
157 N7686d27e7c1a4cfba2fc1b7ffc49990c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Austria
159 rdf:type schema:DefinedTerm
160 N779b7c7f5088463abb612a90c7593f1b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Female
162 rdf:type schema:DefinedTerm
163 N7ac13299800a4ba2a568b3fae599705f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Overweight
165 rdf:type schema:DefinedTerm
166 N7b97f25c25584e38837ba6ad0943866c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Retrospective Studies
168 rdf:type schema:DefinedTerm
169 N80e22f95b21d4b3ca7c2937c82e7a7a4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Body Mass Index
171 rdf:type schema:DefinedTerm
172 N863cc56ffdd54c40a08585c3acf983c7 schema:name Springer Nature - SN SciGraph project
173 rdf:type schema:Organization
174 N8edab4d54ec74a2b90ad40f1652ec64e schema:volumeNumber 21
175 rdf:type schema:PublicationVolume
176 N8fb55d9b26e44541afefaf237e0f187d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Adiposity
178 rdf:type schema:DefinedTerm
179 N94ed771202904745bdc3de2fb6daba2f schema:name dimensions_id
180 schema:value pub.1137484146
181 rdf:type schema:PropertyValue
182 Nafdb561d8a02461b95ef154fe989d49a rdf:first sg:person.011457756430.96
183 rdf:rest rdf:nil
184 Nb41ccba8d81848d6949716d1028b18aa rdf:first N672a52087c6b41de83fac25ad5d79ea9
185 rdf:rest N6f020bb623f544199c11d0d86164c11e
186 Nb77f05813f9943b58d38ffb5dc7b5763 rdf:first sg:person.0757263437.98
187 rdf:rest Nd6fbdc215bb14700a07706a30f0cf322
188 Nbef3386f114e40b8a8fc7fa5a962b8da schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
189 schema:name Male
190 rdf:type schema:DefinedTerm
191 Nc481c19721174401812856ffca695b7d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Hyperprolactinemia
193 rdf:type schema:DefinedTerm
194 Nce6bd85ce846484696ebaf003ae74f22 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
195 schema:name Pituitary Neoplasms
196 rdf:type schema:DefinedTerm
197 Ncf70c322d48b410bae3d4b63bdf0aa3c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
198 schema:name Dyslipidemias
199 rdf:type schema:DefinedTerm
200 Nd5846dd7211d4fb383d8c079a53f3a6f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
201 schema:name Humans
202 rdf:type schema:DefinedTerm
203 Nd6fbdc215bb14700a07706a30f0cf322 rdf:first sg:person.01071524655.82
204 rdf:rest N05bb7b0865ee4bec8d9a9854a1b7d8f4
205 Nec57d0e2b10e48638493d8124ea9cbe9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
206 schema:name Case-Control Studies
207 rdf:type schema:DefinedTerm
208 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
209 schema:name Medical and Health Sciences
210 rdf:type schema:DefinedTerm
211 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
212 schema:name Clinical Sciences
213 rdf:type schema:DefinedTerm
214 sg:journal.1028426 schema:issn 1472-6823
215 schema:name BMC Endocrine Disorders
216 schema:publisher Springer Nature
217 rdf:type schema:Periodical
218 sg:person.01071524655.82 schema:affiliation grid-institutes:grid.11598.34
219 schema:familyName Obermayer-Pietsch
220 schema:givenName Barbara
221 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01071524655.82
222 rdf:type schema:Person
223 sg:person.011457756430.96 schema:affiliation grid-institutes:grid.11598.34
224 schema:familyName Theiler-Schwetz
225 schema:givenName Verena
226 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011457756430.96
227 rdf:type schema:Person
228 sg:person.01201252150.71 schema:affiliation grid-institutes:grid.11598.34
229 schema:familyName Trummer
230 schema:givenName Christian
231 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01201252150.71
232 rdf:type schema:Person
233 sg:person.01351004310.93 schema:affiliation grid-institutes:grid.11598.34
234 schema:familyName Aberer
235 schema:givenName Felix
236 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01351004310.93
237 rdf:type schema:Person
238 sg:person.015231525635.58 schema:affiliation grid-institutes:grid.11598.34
239 schema:familyName Pandis
240 schema:givenName Marlene
241 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015231525635.58
242 rdf:type schema:Person
243 sg:person.0751717266.10 schema:affiliation grid-institutes:grid.11598.34
244 schema:familyName Pilz
245 schema:givenName Stefan
246 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0751717266.10
247 rdf:type schema:Person
248 sg:person.0757263437.98 schema:affiliation grid-institutes:grid.11598.34
249 schema:familyName Pieber
250 schema:givenName Thomas R.
251 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0757263437.98
252 rdf:type schema:Person
253 sg:pub.10.1007/bf03345636 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028831522
254 https://doi.org/10.1007/bf03345636
255 rdf:type schema:CreativeWork
256 sg:pub.10.1007/s11011-016-9882-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034492836
257 https://doi.org/10.1007/s11011-016-9882-2
258 rdf:type schema:CreativeWork
259 sg:pub.10.1007/s12020-012-9857-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1032398967
260 https://doi.org/10.1007/s12020-012-9857-y
261 rdf:type schema:CreativeWork
262 grid-institutes:grid.11598.34 schema:alternateName Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria
263 schema:name Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria
264 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...